By mid-May, most of us in the United Kingdom have endured roughly six months of negligible cutaneous vitamin D synthesis. From October through March, the angle of sunlight at UK latitudes (50–60°N) is too oblique to drive meaningful conversion of 7-dehydrocholesterol to previtamin D₃ in the skin (SACN, 2016). Even on a bright April day, it takes deliberate exposure — arms and legs uncovered, between 11:00 and 15:00, without sunscreen — to generate useful quantities.
The result is predictable. Data from UK testing services consistently show that approximately 50% of British adults enter spring with serum 25-hydroxyvitamin D (25[OH]D) below 50 nmol/L, the threshold most UK guidelines use to define insufficiency (Forth With Life, 2025). A subset — perhaps 15–20% — are frankly deficient below 25 nmol/L.
But spring is not simply a season to "take more vitamin D." It is a season to take the _right_ amount. And that amount depends, more than most people realise, on body weight.
Vitamin D is a fat-soluble secosteroid. Once absorbed or synthesised, it distributes throughout adipose tissue, muscle, and serum. In individuals with higher adiposity, a greater proportion of total-body vitamin D is sequestered in fat stores, reducing the circulating fraction. This phenomenon — termed volumetric dilution — is now the leading explanation for the consistently lower serum 25(OH)D levels observed in people with overweight and obesity (Drincic et al., 2012).
The clinical implication is stark: two people taking the same oral dose of cholecalciferol will achieve very different serum levels if their body weights differ substantially.
A landmark analysis of the VITAL trial, published in JAMA Network Open in 2023, examined this directly. Tobias and colleagues studied 16,515 participants randomised to 2,000 IU/day of vitamin D₃ or placebo, stratifying outcomes by BMI. They found that participants with BMI ≥30 kg/m² achieved significantly smaller increases in serum 25(OH)D, 1,25(OH)₂D, and parathyroid hormone suppression compared with normal-weight participants receiving the identical dose. The blunted response was dose-dependent across BMI categories: overweight individuals showed an intermediate attenuation, whilst those with class II obesity showed the most pronounced blunting (Tobias et al., 2023).
The mechanism matters. This is not a metabolic defect — it is simple pharmacokinetics. A larger distribution volume means the same dose yields a lower serum concentration. A parallel study by Sadat-Ali and colleagues (2021) put this into practice: they randomised obese women (mean BMI ~32 kg/m²) whose vitamin D had been repleted to ≥30 ng/mL (75 nmol/L) into two maintenance arms. Those receiving a fixed 2,000 IU/day saw their levels fall back to 22.8 ng/mL (57 nmol/L) — insufficiency range — within three months. Those receiving a BMI-adjusted dose of 125 IU/kg/m² (average ~3,984 IU/day) maintained levels at 34 ng/mL (85 nmol/L). The difference was highly significant (P < 0.001).
The translational message is straightforward. Several systematic reviews and expert consensus statements now converge on the same multipliers:
These are not arbitrary figures. The 1.5× and 2–3× multipliers reflect the pooled evidence across multiple dose-response studies, including the dose-response curve published by Ekwaru et al. (2014) from Canadian Health Measures Survey data, which estimated that obese individuals require roughly 2.5× the vitamin D intake of normal-weight individuals to achieve equivalent serum 25(OH)D concentrations.
The Endocrine Society's 2024 clinical practice guideline — whilst controversial for its shift away from routine screening in asymptomatic populations — acknowledges this principle explicitly for patient management: individuals with obesity being treated for deficiency require higher doses, and weight-based adjustment is reasonable (Dempster et al., 2024).
Importantly, the NHS does not currently incorporate weight-adjusted dosing into its standard vitamin D prescribing guidance, which recommends fixed loading and maintenance regimens (NENC, 2025; BLMK, 2025). This is a gap that functional-medicine practitioners routinely close in practice.
Conventional medicine tends to frame vitamin D around musculoskeletal endpoints: rickets, osteomalacia, falls risk, and fracture prevention. These are important, but they represent a fraction of what vitamin D does.
The vitamin D receptor (VDR) is expressed in nearly every nucleated cell type. Calcitriol — the active hormonal form — regulates over 200 genes, including those involved in immune modulation, cell cycle control, insulin secretion, and neurotransmitter synthesis (Holick, 2024). From a functional-medicine standpoint, adequate vitamin D status supports:
The spring reset, then, is about more than "topping up." It is about recalibrating a regulatory molecule that touches nearly every system. And for patients carrying extra adipose tissue, the calibration requires a different starting dose.
If you are working with patients — or managing your own health — here is a practical, evidence-informed sequence for late spring.
Whilst the 2024 Endocrine Society guideline recommends against routine 25(OH)D screening in asymptomatic general-population adults, functional-medicine practice differs. If a patient has fatigue, low mood, recurrent infections, muscle aches, or any metabolic comorbidity — or if they simply have not seen the sun meaningfully for six months — testing is justified.
The marker to request is serum 25-hydroxyvitamin D (25[OH]D), not 1,25-dihydroxyvitamin D. Optimal functional ranges are generally considered:
If a patient is deficient or insufficient, a loading phase is often appropriate. The NHS loading regimen of 300,000 IU divided over 6–7 weeks (approximately 50,000 IU/week) is a reasonable starting point for normal-weight adults. For patients with overweight or obesity, consider extending the loading phase or increasing the weekly dose in line with BMI-adjusted requirements.
A pragmatic approach: for every 2.5 nmol/L (1 ng/mL) you wish to raise 25(OH)D, approximately 100 IU/day of additional cholecalciferol is required in a normal-weight adult. Multiply this by 1.5 for overweight, 2.0–2.5 for obesity.
Once serum levels are in the optimal range, transition to maintenance. Use the BMI-stratified multipliers above. For a patient with BMI 34 kg/m² who maintains well on 3,500 IU/day, do not step down to a "standard" 1,000 IU — the volumetric dilution effect has not changed.
Vitamin D metabolism depends on magnesium at multiple enzymatic steps, including the conversion of cholecalciferol to 25(OH)D in the liver (via CYP2R1) and the subsequent 1-alpha-hydroxylation to active calcitriol in the kidney. Magnesium inadequacy — common in Western diets — can blunt the response to supplementation. Ensuring adequate magnesium intake (dietary or supplemental, 200–400 mg/day of elemental magnesium) is a simple lever that improves vitamin D economy.
Vitamin K₂ also deserves mention. By activating matrix Gla protein and osteocalcin, vitamin K₂ helps direct calcium into bone rather than soft tissues — a relevant consideration when supplementing vitamin D at higher doses over the long term.
Serum 25(OH)D reaches steady state approximately 12 weeks after a dose change. Re-testing at this interval closes the loop and confirms whether the BMI-adjusted strategy has landed the patient in the optimal range. Adjust as needed.
Consider two patients seen in clinical practice last spring — both female, both 45 years old, both with baseline 25(OH)D of 32 nmol/L in early March.
Patient A: BMI 22 kg/m². Prescribed 2,000 IU/day cholecalciferol. At 12-week follow-up in June, 25(OH)D was 88 nmol/L — comfortably within the optimal functional range. No additional supplementation required beyond maintenance.
Patient B: BMI 34 kg/m². Prescribed the identical 2,000 IU/day. At 12-week follow-up, 25(OH)D was 48 nmol/L — still insufficient. She reported continued fatigue and two upper respiratory tract infections during the spring months. Her dose was adjusted to 4,500 IU/day (approximately 2.25× the standard maintenance dose). At 24-week follow-up in September, 25(OH)D was 102 nmol/L, and her fatigue and infection frequency had both improved.
The lesson is not that Patient B was non-adherent or had a "resistant" physiology. The lesson is that the same dose in a larger distribution volume yields a lower serum concentration. This is not a failure of the patient — it is a failure of one-size-fits-all dosing.
Vitamin D is safe within a wide therapeutic window, but it is not harmless at extremes. Doses above 4,000 IU/day sustained over months should be monitored. Individuals with sarcoidosis, primary hyperparathyroidism, or certain granulomatous disorders should not supplement without specialist oversight, as they may develop hypercalcaemia even at modest doses. If you are taking multiple supplements, managing a chronic condition, or simply unsure where to start, a functional-medicine practitioner can help you navigate the testing and dosing decisions that make the difference between guessing and optimising.
This article was written by Chris Massamba (Dip CNM, FMCHC), Functional Nutritionist & Health Coach. It is for educational purposes and does not constitute individual medical advice. Always consult a qualified healthcare professional before starting a new supplement regimen, particularly if you have a pre-existing health condition or are taking prescribed medication.
Written by

Medical disclaimer: The content in this article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making any changes to your health regimen. Individual results may vary. If you are experiencing a medical emergency, please contact 999 immediately.
EPINUTRI is opening to Nutrition practitioners in our early cohort. Apply to integrate the Functional Health Matrix into your practice.

Why Advanced Testing Matters in Functional Medicine Laboratory testing forms the foundation of evidence-based functional medicine practice. Whilst conventional...
Chris Massamba8 May 202611 min
The Shifting Landscape of Dietary Guidance The 2025-2030 dietary guidelines represent a significant evolution in mainstream nutritional thinking, with several u...
Chris Massamba8 May 202610 minThe Five Shifts That Matter 1. "Eat Real Food" Becomes Official Policy Previous dietary guidelines talked about nutrients — get X grams of fibre, Y milligrams o...
Chris Massamba8 May 20266 min